Sarkaria et al identified prognostic classes of high grade malignant gliomas using RTOG (Radiation Therapy Oncology Group) analysis. These can help compare outcomes following therapeutic interventions. The authors are from the University of Wisconsin, Harvard University and the University of Florida at Gainesville.
Selection criteria included age > 18 years.
Parameter:
(1) type (anaplastic astrocytoma vs glioblastoma multiforme)
(2) age of the patient
(3) mental status
(4) Karnofsky performance scale (KPS)
(5) duration of symptoms before diagnosis
(6) functional status
(7) surgery (partial or total resection vs biopsy)
Anaplastic Astrocytoma
Parameter |
Class 1 |
Class 2 |
Class 3 |
age in years |
< 50 years |
>= 50 years |
< 50 years |
mental status |
normal |
|
abnormal |
KPS |
|
>= 70 |
|
duration |
|
> 3 months |
|
functional status |
|
|
|
surgery |
|
|
|
Parameter |
Class 4 |
Class 5 |
Class 6 |
age in years |
>= 50 years |
>= 50 years |
>= 50 years |
mental status |
|
normal |
abnormal |
KPS |
>= 70 |
< 70 |
< 70 |
duration |
<= 3 months |
|
|
functional status |
|
|
|
surgery |
|
|
|
Glioblastoma Multiforme
Parameter |
Class 3 |
Class 4a |
Class 4b |
age in years |
< 50 years |
< 50 years |
>= 50 |
mental status |
|
|
|
KPS |
>= 90 |
< 90 |
>= 70 |
duration |
|
|
|
functional status |
|
|
working |
surgery |
|
|
resection |
Parameter |
Class 5a |
Class 5b |
Class 5c |
age in years |
>= 50 |
>= 50 |
>= 50 |
mental status |
|
|
normal |
KPS |
>= 70 |
>= 70 |
< 70 |
duration |
|
|
|
functional status |
not working |
|
|
surgery |
resection |
biopsy |
|
Parameter |
Class 6 |
age in years |
>= 50 years |
mental status |
abnormal |
KPS |
< 70 |
duration |
|
functional status |
|
surgery |
|
Patients were treated with surgery, external beam radiation and linac-based radiosurgery.
Prognostic classes 1, 2 and 3 had a relatively favorable outcome with survival at 2 years from 75-81% (75% at 3 years for 1 and 2, 45% at 3 years for group 3).
Prognostic classes 4, 5 and 6 had a relatively unfavorable outcome with survival at 2 years from 21-34% (< 10% at 3 years).
Specialty: Hematology Oncology, Surgery, general, Neurology